Mao-Wang Ho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mao-Wang Ho has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Chih-Yu Chi
Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
4 shared publications Po-Chang Lin
Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
4 shared publicationsCheng-Mao Ho
Department of Laboratory Medicine, Taichung, Taiwan; Internal Medicine, China Medical University Hospital, Taichung, Taiwan; Department of Nursing, Hungkuang University, Taichung, Taiwan
3 shared publicationsChia-Huei Chou
China Med Univ Hosp, Taichung, Taiwan
3 shared publicationsChia-Hui Chou
Division of Infection Disease, Department of Internal Medicine, China Medical University Hospital, Taichung City, Taiwan, R.O.C
3 shared publicationsChia-Ta Tsai
Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
3 shared publications
Latest Publications
- Open Access
- 6 January 2025
- Published by MDPI AG in Preprints.org
Week 48 Results from Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/ Tenofovir Alafenamide Fumarate: Real-World Assessment of Weight Gain in Naïve People Living with HIV of Asian OrigiN (Dragon)
Several studies have demonstrated that significant weight gain occurs in some people living with HIV (PWH) after initiating integrase strand transfer inhibitors (INSTIs). Most studies on weight change have been clinical trials primarily focused on Africa, Europe, and North America, with limited representation from real-world studies in Asia. This retrospective observational study, conducted at nine designated HIV-care hospitals from March 2019 to January 2024, aimed to address this gap. Of the 533 patients screened, 314 met the criteria for the BIC/FTC/TAF group, while 181 qualified for the DTG/3TC group. At week 48, 86.3% of patients in the DTG/3TC group and 84.8% in the BIC/FTC/TAF group achieved HIV RNA <50 copies/mL (difference: 1.5%; 95% CI: -5.4% to 8.4%; p=0.67, evaluated in a snapshot, per-protocol-exposed population), meeting the criteria of non-inferiority. After calculating inverse probability of treatment weights, logistic regression analysis identified the following risk factors for weight gain of ≥10% at week 48: BIC/FTC/TAF (aOR 1.72; 95% CI: 1.16–2.54; p<0.01), CD4 counts <200 cells/uL (aOR 2.00; 95% CI: 1.32–3.03; p<0.01), HIV RNA ≥100,000 copies/mL (aOR 2.05; 95% CI: 1.37–3.07; p<0.01), and BMI <24 (aOR 3.51, 95% CI: 2.29–5.37, p<0.01). In conclusion, the study demonstrates that INSTIs, particularly BIC/FTC/TAF, may lead to significant weight gain in Asia. Furthermore, consistently high and comparable effectiveness was observed in both the BIC/FTC/TAF and DTG/3TC groups. Prospective studies involving a larger number of patients are warranted to further explore these findings.
- 6 January 2025
- Published by MDPI AG in Preprints.org
Open AccessWeek 48 Results from Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/ Tenofovir Alafenamide Fumarate: Real-World Assessment of Weight Gain in Naïve People Living with HIV of Asian OrigiN (Dragon)
Several studies have demonstrated that significant weight gain occurs in some people living with HIV (PWH) after initiating integrase strand transfer inhibitors (INSTIs). Most studies on weight change have been clinical trials primarily focused on Africa, Europe, and North America, with limited representation from real-world studies in Asia. This retrospective observational study, conducted at nine designated HIV-care hospitals from March 2019 to January 2024, aimed to address this gap. Of the 533 patients screened, 314 met the criteria for the BIC/FTC/TAF group, while 181 qualified for the DTG/3TC group. At week 48, 86.3% of patients in the DTG/3TC group and 84.8% in the BIC/FTC/TAF group achieved HIV RNA <50 copies/mL (difference: 1.5%; 95% CI: -5.4% to 8.4%; p=0.67, evaluated in a snapshot, per-protocol-exposed population), meeting the criteria of non-inferiority. After calculating inverse probability of treatment weights, logistic regression analysis identified the following risk factors for weight gain of ≥10% at week 48: BIC/FTC/TAF (aOR 1.72; 95% CI: 1.16–2.54; p<0.01), CD4 counts <200 cells/uL (aOR 2.00; 95% CI: 1.32–3.03; p<0.01), HIV RNA ≥100,000 copies/mL (aOR 2.05; 95% CI: 1.37–3.07; p<0.01), and BMI <24 (aOR 3.51, 95% CI: 2.29–5.37, p<0.01). In conclusion, the study demonstrates that INSTIs, particularly BIC/FTC/TAF, may lead to significant weight gain in Asia. Furthermore, consistently high and comparable effectiveness was observed in both the BIC/FTC/TAF and DTG/3TC groups. Prospective studies involving a larger number of patients are warranted to further explore these findings.
- 1 February 2023
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 29 (2) , 447-448
Cryptococcus tetragattii Meningitis Associated with Travel, Taiwan
Meningitis caused by Cryptococcus tetragattii fungus is rare and has been found in specific geographic regions. We report a case of meningitis caused by C. tetragattii (molecular type VGIV) in an immunocompetent patient in Taiwan. The patient had traveled to Egypt and was positive for granulocyte-macrophage colony-stimulating factor autoantibody.
- 1 February 2023
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 29 (2) , 447-448
Cryptococcus tetragattii Meningitis Associated with Travel, Taiwan
Meningitis caused by Cryptococcus tetragattii fungus is rare and has been found in specific geographic regions. We report a case of meningitis caused by C. tetragattii (molecular type VGIV) in an immunocompetent patient in Taiwan. The patient had traveled to Egypt and was positive for granulocyte-macrophage colony-stimulating factor autoantibody.
- Open Access
- 21 August 2022
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 55 (6) , 1283-1292
Definite therapy of mixed infection alleviates refractory dilemma of adult chronic suppurative otitis media
- 21 August 2022
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 55 (6) , 1283-1292
Open AccessDefinite therapy of mixed infection alleviates refractory dilemma of adult chronic suppurative otitis media
- Open Access
- 1 February 2022
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 55 (1) , 175-176
Rat-bite fever with bacteremia and lower limb abscess formation caused by Streptobacillus moniliformis
- 1 February 2022
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 55 (1) , 175-176
Open AccessRat-bite fever with bacteremia and lower limb abscess formation caused by Streptobacillus moniliformis
- Open Access
- 12 March 2020
- Published by MDPI AG in Microorganisms
- Vol. 8 (3) , 397
Long-Term Surveillance of Antibiotic Prescriptions and the Prevalence of Antimicrobial Resistance in Non-Fermenting Gram-Negative Bacilli
The increasing emergence of multidrug-resistant (MDR) bacteria has been recognized as a public health threat worldwide. Hospitalized patients and outpatients are commonly infected by non-fermenting Gram-negative bacilli (NFGNB), particularly the Acinetobacter calcoaceticus-Acinetobacter baumannii complex (ACB) and Pseudomonas aeruginosa. Antimicrobial agents are critical for treating the nosocomial infections caused by NFGNB. The aim of this study was to assess antimicrobial resistance and the use of antimicrobial agents. The bacterial isolates of 638,152 specimens from both inpatients and outpatients, retrieved from 2001 to 2008 at a medical center in central Taiwan, were examined for their susceptibility to various antimicrobial agents, including cefepime, imipenem, ciprofloxacin, gentamicin, amikacin, meropenem, and levofloxacin. Administrated prescriptions of the monitored antibiotics were analyzed using the Taiwan National Health Insurance Research Database (NHIRD). Our results show that the defined daily doses (DDDs) for cefepime, imipenem, and ciprofloxacin increased with time, and a trend toward reduced antimicrobial sensitivities of both ACB and P. aeruginosa was noticeable. In conclusion, the antimicrobial sensitivities of ACB and P. aeruginosa were reduced with the increased use of antibiotics. Continuous surveillance of antibiotic prescriptions and the prevalence of emerging resistance in nosocomial infections is warranted.
- 12 March 2020
- Published by MDPI AG in Microorganisms
- Vol. 8 (3) , 397
Open AccessLong-Term Surveillance of Antibiotic Prescriptions and the Prevalence of Antimicrobial Resistance in Non-Fermenting Gram-Negative Bacilli
The increasing emergence of multidrug-resistant (MDR) bacteria has been recognized as a public health threat worldwide. Hospitalized patients and outpatients are commonly infected by non-fermenting Gram-negative bacilli (NFGNB), particularly the Acinetobacter calcoaceticus-Acinetobacter baumannii complex (ACB) and Pseudomonas aeruginosa. Antimicrobial agents are critical for treating the nosocomial infections caused by NFGNB. The aim of this study was to assess antimicrobial resistance and the use of antimicrobial agents. The bacterial isolates of 638,152 specimens from both inpatients and outpatients, retrieved from 2001 to 2008 at a medical center in central Taiwan, were examined for their susceptibility to various antimicrobial agents, including cefepime, imipenem, ciprofloxacin, gentamicin, amikacin, meropenem, and levofloxacin. Administrated prescriptions of the monitored antibiotics were analyzed using the Taiwan National Health Insurance Research Database (NHIRD). Our results show that the defined daily doses (DDDs) for cefepime, imipenem, and ciprofloxacin increased with time, and a trend toward reduced antimicrobial sensitivities of both ACB and P. aeruginosa was noticeable. In conclusion, the antimicrobial sensitivities of ACB and P. aeruginosa were reduced with the increased use of antibiotics. Continuous surveillance of antibiotic prescriptions and the prevalence of emerging resistance in nosocomial infections is warranted.
- Open Access
- 12 November 2019
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 8 (1) , 1-11
Risk prediction for 30-day mortality among patients with Clostridium difficile infections: a retrospective cohort study
Background: Current guidelines have unsatisfied performance in predicting severe outcomes after Clostridium difficile infection (CDI). Our objectives were to develop a risk prediction model for 30-day mortality and to examine its performance among inpatients with CDI. Methods: This retrospective cohort study was conducted at China Medical University Hospital, a 2111-bed tertiary medical center in central Taiwan. We included adult inpatients who had a first positive C. difficile culture or toxin assay and had diarrhea as the study population. The main exposure of interest was the biochemical profiles of white blood cell count, serum creatinine (SCr), estimated glomerular filtration rate, blood urea nitrogen (BUN), serum albumin, and glucose. The primary outcome was the 30-day all-cause mortality and the secondary outcome was the length of stay in the intensive care units (ICU) following CDI. A multivariable Cox model and a logistic regression model were developed using clinically relevant and statistically significant variables for 30-day mortality and for length of ICU stay, respectively. A risk scoring system was established by standardizing the coefficients. We compared the performance of our models and the guidelines. Results: Of 401 patients, 23.4% died within 30 days. In the multivariable model, malignancy (hazard ratio [HR] = 1.95), ≥ 1.5-fold rise in SCr (HR = 2.27), BUN-to-SCr ratio > 20 (HR = 2.04), and increased glucose (≥ 193 vs < 142 mg/dL, HR = 2.18) were significant predictors of 30-day mortality. For patients who survived the first 30 days of CDI, BUN-to-SCr ratio > 20 (Odds ratio [OR] = 4.01) was the only significant predictor for prolonged (> 9 days) length of ICU stay following CDI. The Harrell’s c statistic of our Cox model for 30-day mortality (0.727) was significantly superior to those of SHEA-IDSA 2010 (0.645), SHEA-IDSA 2018 (0.591), and ECSMID (0.650). Similarly, the conventional c statistic of our logistic regression model for prolonged ICU stay (0.737) was significantly superior to that of the guidelines (SHEA-IDSA 2010, c = 0.600; SHEA-IDSA 2018, c = 0.634; ESCMID, c = 0.645). Our risk prediction scoring system for 30-day mortality correctly reclassified 20.7, 32.1, and 47.9% of patients, respectively. Conclusions: Our model that included novel biomarkers of BUN-to-SCr ratio and glucose have a higher predictive performance of 30-day mortality and prolonged ICU stay following CDI than do the guidelines.
- 12 November 2019
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 8 (1) , 1-11
Open AccessRisk prediction for 30-day mortality among patients with Clostridium difficile infections: a retrospective cohort study
Background: Current guidelines have unsatisfied performance in predicting severe outcomes after Clostridium difficile infection (CDI). Our objectives were to develop a risk prediction model for 30-day mortality and to examine its performance among inpatients with CDI. Methods: This retrospective cohort study was conducted at China Medical University Hospital, a 2111-bed tertiary medical center in central Taiwan. We included adult inpatients who had a first positive C. difficile culture or toxin assay and had diarrhea as the study population. The main exposure of interest was the biochemical profiles of white blood cell count, serum creatinine (SCr), estimated glomerular filtration rate, blood urea nitrogen (BUN), serum albumin, and glucose. The primary outcome was the 30-day all-cause mortality and the secondary outcome was the length of stay in the intensive care units (ICU) following CDI. A multivariable Cox model and a logistic regression model were developed using clinically relevant and statistically significant variables for 30-day mortality and for length of ICU stay, respectively. A risk scoring system was established by standardizing the coefficients. We compared the performance of our models and the guidelines. Results: Of 401 patients, 23.4% died within 30 days. In the multivariable model, malignancy (hazard ratio [HR] = 1.95), ≥ 1.5-fold rise in SCr (HR = 2.27), BUN-to-SCr ratio > 20 (HR = 2.04), and increased glucose (≥ 193 vs < 142 mg/dL, HR = 2.18) were significant predictors of 30-day mortality. For patients who survived the first 30 days of CDI, BUN-to-SCr ratio > 20 (Odds ratio [OR] = 4.01) was the only significant predictor for prolonged (> 9 days) length of ICU stay following CDI. The Harrell’s c statistic of our Cox model for 30-day mortality (0.727) was significantly superior to those of SHEA-IDSA 2010 (0.645), SHEA-IDSA 2018 (0.591), and ECSMID (0.650). Similarly, the conventional c statistic of our logistic regression model for prolonged ICU stay (0.737) was significantly superior to that of the guidelines (SHEA-IDSA 2010, c = 0.600; SHEA-IDSA 2018, c = 0.634; ESCMID, c = 0.645). Our risk prediction scoring system for 30-day mortality correctly reclassified 20.7, 32.1, and 47.9% of patients, respectively. Conclusions: Our model that included novel biomarkers of BUN-to-SCr ratio and glucose have a higher predictive performance of 30-day mortality and prolonged ICU stay following CDI than do the guidelines.
- Open Access
- 16 May 2019
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 14 (1) , 1-11
A preliminary study of the novel antibiotic-loaded cement computer-aided design-articulating spacer for the treatment of periprosthetic knee infection
In comparison to static spacers, articulating spacers have been shown to result in a similar infection eradication rate in two-stage revision of periprosthetic knee infections. However, the optimal construct for articulating spacers has not been identified yet. The aim of this study was to present a preliminary result of treatment for periprosthetic knee infection using a novel computer-aided design (CAD)-articulating spacer. We retrospectively reviewed 32 consecutive cases of chronic periprosthetic knee infection occurring from January 2015 to December 2015. In these cases, we used an antibiotic-loaded, optimized CAD-articulating spacer based on the retrieved knee prosthesis. Evaluation included infection eradication rate, the Hospital of Special Surgery (HSS) knee score, range of motion (ROM), and spacer-related mechanical complications. All cases were regularly followed-up for 2 years minimum. Twenty-eight of 32 patients (87.5%) had infection eradication; 18 patients (56.3%) received reimplantation successfully. The mean interval between spacer insertion and reimplantation was 8.8 months (range 4.0–12.5 months). The mean HSS knee score and ROM significantly increased during each interval (p < 0.0001 for both). The mean HSS knee scores were 31.2 (range 20–48) at initial visit, 65.4 (range 60–78.8) at 1 month after spacer insertion, and 84.2 (range 78–90) at 3 months after reimplantation (p < 0.0001). The mean ROM were 72.0° (range 15–100°), 85.6° (range 35–110°), and 102.0° (range 80–122°), respectively (p = 0.002). Two (6.3%) spacer-related mechanical complications occurred. The CAD-articulating spacer in two-staged revision of periprosthetic knee infection significantly controlled infection, improved clinical outcomes, increased ROM, and decreased mechanical complications in the preliminary study. Further larger clinical studies are needed to confirm the findings presented here.
- 16 May 2019
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 14 (1) , 1-11
Open AccessA preliminary study of the novel antibiotic-loaded cement computer-aided design-articulating spacer for the treatment of periprosthetic knee infection
In comparison to static spacers, articulating spacers have been shown to result in a similar infection eradication rate in two-stage revision of periprosthetic knee infections. However, the optimal construct for articulating spacers has not been identified yet. The aim of this study was to present a preliminary result of treatment for periprosthetic knee infection using a novel computer-aided design (CAD)-articulating spacer. We retrospectively reviewed 32 consecutive cases of chronic periprosthetic knee infection occurring from January 2015 to December 2015. In these cases, we used an antibiotic-loaded, optimized CAD-articulating spacer based on the retrieved knee prosthesis. Evaluation included infection eradication rate, the Hospital of Special Surgery (HSS) knee score, range of motion (ROM), and spacer-related mechanical complications. All cases were regularly followed-up for 2 years minimum. Twenty-eight of 32 patients (87.5%) had infection eradication; 18 patients (56.3%) received reimplantation successfully. The mean interval between spacer insertion and reimplantation was 8.8 months (range 4.0–12.5 months). The mean HSS knee score and ROM significantly increased during each interval (p < 0.0001 for both). The mean HSS knee scores were 31.2 (range 20–48) at initial visit, 65.4 (range 60–78.8) at 1 month after spacer insertion, and 84.2 (range 78–90) at 3 months after reimplantation (p < 0.0001). The mean ROM were 72.0° (range 15–100°), 85.6° (range 35–110°), and 102.0° (range 80–122°), respectively (p = 0.002). Two (6.3%) spacer-related mechanical complications occurred. The CAD-articulating spacer in two-staged revision of periprosthetic knee infection significantly controlled infection, improved clinical outcomes, increased ROM, and decreased mechanical complications in the preliminary study. Further larger clinical studies are needed to confirm the findings presented here.
- Open Access
- 1 August 2018
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 51 (4) , 552-558
Clinical features, antifungal susceptibility, and outcome of Candida guilliermondii fungemia: An experience in a tertiary hospital in mid-Taiwan
- 1 August 2018
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 51 (4) , 552-558
Open AccessClinical features, antifungal susceptibility, and outcome of Candida guilliermondii fungemia: An experience in a tertiary hospital in mid-Taiwan
- Open Access
- 8 June 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0197851
Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study
This study investigated the epidemiology and risk factors associated with invasive fungal infections (IFIs) during induction chemotherapy in a cohort of Taiwanese patients with newly-diagnosed acute myeloid leukemia (AML). IFIs are a significant complication in the management of immunocompromised cancer patients; such infections are associated with a high incidence of morbidity and mortality, particularly in many South-Asian countries, where IFI rates are increasing. We retrospectively analyzed IFI incidence data from 105 patients with newly diagnosed AML at a single center undergoing their first course of induction chemotherapy without primary antifungal prophylaxis between November 2008 and December 2014. Of 21 cases documented as proven/provable IFIs 16 (76%) were invasive aspergillosis, 2 (10%) were mucormycosis infections, and 3 (14%) were proven yeast infections. The lung was the most commonly affected site (n = 16; 76%); 2 patients (10%) developed fungal sinusitis. IFI cases were more often males (P = 0.020). In multivariate analysis, patients with neutropenia lasting>30 days were more than twice as likely to develop IFI (OR, 2.24 [95% CI, 2.81–31.11], P<0.001). We also confirmed patients with smoker and receiving parenteral nutrition during chemotherapy were significant associated with IFIs. Our findings suggest that antifungal prophylaxis should be considered for patients with AML during induction chemotherapy, particularly in patients from Southeastern Asia, an area of potentially high IFI rates. We recommend that clinicians determine which patients receiving induction chemotherapy for AML are at high risk of developing IFI, to allow for targeted therapeutic prophylaxis.
- 8 June 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0197851
Open AccessEpidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study
This study investigated the epidemiology and risk factors associated with invasive fungal infections (IFIs) during induction chemotherapy in a cohort of Taiwanese patients with newly-diagnosed acute myeloid leukemia (AML). IFIs are a significant complication in the management of immunocompromised cancer patients; such infections are associated with a high incidence of morbidity and mortality, particularly in many South-Asian countries, where IFI rates are increasing. We retrospectively analyzed IFI incidence data from 105 patients with newly diagnosed AML at a single center undergoing their first course of induction chemotherapy without primary antifungal prophylaxis between November 2008 and December 2014. Of 21 cases documented as proven/provable IFIs 16 (76%) were invasive aspergillosis, 2 (10%) were mucormycosis infections, and 3 (14%) were proven yeast infections. The lung was the most commonly affected site (n = 16; 76%); 2 patients (10%) developed fungal sinusitis. IFI cases were more often males (P = 0.020). In multivariate analysis, patients with neutropenia lasting>30 days were more than twice as likely to develop IFI (OR, 2.24 [95% CI, 2.81–31.11], P<0.001). We also confirmed patients with smoker and receiving parenteral nutrition during chemotherapy were significant associated with IFIs. Our findings suggest that antifungal prophylaxis should be considered for patients with AML during induction chemotherapy, particularly in patients from Southeastern Asia, an area of potentially high IFI rates. We recommend that clinicians determine which patients receiving induction chemotherapy for AML are at high risk of developing IFI, to allow for targeted therapeutic prophylaxis.
- 1 May 2016
- Published by Elsevier in Journal of Infection
- Vol. 72 (5) , 608-614
Diabetes mellitus is associated with acquisition and increased mortality in HIV-uninfected patients with cryptococcosis: A population-based study
- 1 May 2016
- Published by Elsevier in Journal of Infection
- Vol. 72 (5) , 608-614
Diabetes mellitus is associated with acquisition and increased mortality in HIV-uninfected patients with cryptococcosis: A population-based study